Clinical Significance of Soluble LAG-3 (sLAG-3) in Patients With Cervical Cancer Determined via Enzyme-Linked Immunosorbent Assay With Monoclonal Antibodies
Technology in Cancer Research & Treatment · 2023
DOI: 10.1177/15330338231202650 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2023. Verfasst von Yang Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Program of clinical medicine expert team of Suzhou, China, The Science and Technology Project of Suzhou, The Suzhou Medical Key Discipline Funding Project.
Abstract (Originalsprache)
Background
The tumor microenvironment and tumor immunity have become the focus of research on tumor diagnosis and treatment. Lymphocyte activation gene-3 (LAG-3, CD223) is a newly discovered immunosuppressive receptor that is abnormally expressed in various tumor microenvironments and plays an important role as an immune checkpoint in the tumor immune response.
Objective
We developed a novel enzyme-linked immunosorbent assay kit, examined the levels of soluble LAG-3 (sLAG-3) in the serum of patients with cervical cancer, and identified new biomarkers for cervical cancer development.
Methods
To investigate the potential biological function of sLAG-3, we generated and characterized 2 novel anti-LAG-3 monoclonal antibodies, namely 4F4 and 4E12. We performed western blotting, immunofluorescence, and immunohistochemistry using hybridoma technology and an enzyme-linked immunosorbent assay kit for detecting human sLAG-3 based on an improved double-antibody sandwich enzyme-linked immunosorbent assay method. The stability and sensitivity of these kits were also assessed.
Results
We screened and characterized 2 novel monoclonal antibodies against human LAG-3. The enzyme-linked immunosorbent assay kit also includes a wide range of tests. Using this enzyme-linked immunosorbent assay system, we found that the expression level of sLAG-3 in the peripheral blood of patients with cervical cancer significantly decreased as the disease progressed ( P < .0001). Multivariate logistic regression analysis revealed that low sLAG-3 expression was an independent predictor of cervical cancer and related diseases ( P < .05). Furthermore, receiver operating characteristic curve analysis showed that sLAG-3 had diagnostic value for cervical cancer metastasis ( P < .0001).
Conclusion
These data suggest that sLAG-3 is a potential biomarker for cervical cancer development. Therefore, this kit has a certain application value in the diagnosis of cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- Department of Gynecology and Obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- Department of General surgery, The Affiliated Jiangsu Shengze Hospital of Nanjing Medical University, Suzhou, Jiangsu, China.
- Suzhou Red Cross Blood Station, Suzhou, Jiangsu, China.
ORCID-Profile: Yanzheng Gu
Förderung
- The Program of clinical medicine expert team of Suzhou, China
- The Science and Technology Project of Suzhou
- The Suzhou Medical Key Discipline Funding Project
- The Health Science and Technology Program of Suzhou
Zitieren
APA
Li, Y., Wang, W., Tian, J., Zhou, Y., Shen, Y., Wang, M., Tang, L., Liu, C., Zhang, X., Shen, F., Chen, Y., & Gu, Y. (2023). Clinical Significance of Soluble LAG-3 (sLAG-3) in Patients With Cervical Cancer Determined via Enzyme-Linked Immunosorbent Assay With Monoclonal Antibodies. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338231202650
Vancouver
Li Y, Wang W, Tian J, Zhou Y, Shen Y, Wang M, et al. Clinical Significance of Soluble LAG-3 (sLAG-3) in Patients With Cervical Cancer Determined via Enzyme-Linked Immunosorbent Assay With Monoclonal Antibodies. Technology in Cancer Research & Treatment. 2023. doi:10.1177/15330338231202650
BibTeX
@article{Li2023,
author = {Li, Yang and Wang, Wenwen and Tian, Jingluan and Zhou, Ying and Shen, Yu and Wang, Mingyuan and Tang, Longhai and Liu, Cuiping and Zhang, Xueguang and Shen, Fangrong and Chen, Youguo and Gu, Yanzheng},
title = {Clinical Significance of Soluble LAG-3 (sLAG-3) in Patients With Cervical Cancer Determined via Enzyme-Linked Immunosorbent Assay With Monoclonal Antibodies},
journal = {Technology in Cancer Research & Treatment},
year = {2023},
doi = {10.1177/15330338231202650}
}
EUVIMED